LogoPeqSERPE
logoCabeceraNinos

Hemos leído sobre ... Síndrome de activación Macrofágica

Última actualización: 21 septiembre 2022
 
 
 
AGOSTO 2022
  • Levy O, Apel A, Alhdor H, Mizrachi A, Agmon-Levin N, Koren-Michowitz M, Amit-Vazina M.
    Ruxolitinib for Refractory Macrophage Activation Syndrome complicating Adult-Onset Still's Disease
    Eur J Rheumatol. 2022 Aug 9. doi: 10.5152/eurjrheum.2022.21064. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/35943464/

  • Rainone M, Ngo D, Baird JH, Budde LE, Htut M, Aldoss I, Pullarkat VA.
    Interferon-γ blockade in CART-cell therapy-associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis.
    Blood Adv. 2022 Aug 2:bloodadvances.2022008256. doi: 10.1182/bloodadvances.2022008256. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/35917457/

JULIO 2022
  • Kostik MM, Isupova EA, Belozerov K, Likhacheva TS, Suspitsin EN, Raupov R, Masalova VV, Chikova IA, Dubko MF, Kalashnikova OV, Chasnyk VG, Cron RQ.
    Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis.
    Front Pediatr. 2022 Jul 28;10:894846. doi: 10.3389/fped.2022.894846.
    https://pubmed.ncbi.nlm.nih.gov/35967555/

  • De Matteis A, Colucci M, Rossi MN, Caiello I, Merli P, Tumino N, Bertaina V, Pardeo M, Bracaglia C, Locatelli F, De Benedetti F, Prencipe G.
    Expansion of CD4dimCD8+ T cells characterizes macrophage activation syndrome and other secondary HLH.
    Blood. 2022 Jul 21;140(3):262-273. doi: 10.1182/blood.2021013549.
    https://pubmed.ncbi.nlm.nih.gov/35500103/

MAYO 2022
  • Wang R, Li T, Ye S, Lv L, Chen S, Wang X, Bao CD, Fu Q.
    Short-term, low-dose etoposide in refractory adult-onset Still's disease-associated macrophage activation syndrome.
    lin Rheumatol. 2022 May 19. doi: 10.1007/s10067-022-06184-1. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/35590113/

  • Ding Y, Ge Y.
    Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis complicated with macrophage activation syndrome.
    Ther Adv Chronic Dis. 2022 May 13;13:20406223221098128. doi: 10.1177/20406223221098128.
    https://pubmed.ncbi.nlm.nih.gov/35586303/

  • Bossi G, Codazzi AC, Vinci F, Clerici E, Regalbuto C, Crapanzano C, Veraldi D, Moiraghi A, Marseglia GL.
    Efficacy of Anakinra on Multiple Coronary Arteries Aneurysms in an Infant with Recurrent Kawasaki Disease, Complicated by Macrophage Activation Syndrome.
    Children (Basel). 2022 May 5;9(5):672. doi: 10.3390/children9050672.
    https://pubmed.ncbi.nlm.nih.gov/35626849/

 
MARZO 2022
  • Naniwa T, Yamabe T, Ohmura SI, Uehara K, Tamechika SY, Maeda S, Isogai S, Wada J.
    Baseline clinical features predicting macrophage activation syndrome in patients with systemic adult-onset Still's disease receiving interleukin-6 inhibitor treatment.
    Int J Rheum Dis. 2022 Jun 19. doi: 10.1111/1756-185X.14371. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/35719030/

  • Lahiry P, Naumenko S, Couse M, Liao F, Dominguez D, Knight A, Levy DM, Misztal M, Ng LWK, Hiraki LT.
    Hemophagocytic Lymphohistiocytosis Gene Variants in Childhood-Onset SLE with Macrophage Activation Syndrome.
    J Rheumatol. 2022 Jun 1:jrheum.211200. doi: 10.3899/jrheum.211200. Epub ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/35649546/

 
MARZO 2022
  • Fingerhutová Š, Jančová E, Doležalová P.
    Anakinra in Paediatric Rheumatology and Periodic Fever Clinics: Is the Higher Dose Safe?
    Front Pediatr. 2022 Mar 7;10:823847. doi: 10.3389/fped.2022.823847
    https://pubmed.ncbi.nlm.nih.gov/35321008/

  • Vagrecha A, Zhang M, Acharya S, Lozinsky S, Singer A, Levine C, Al-Ghafry M, Fein Levy C, Cron RQ.
    Hemophagocytic Lymphohistiocytosis Gene Variants in Multisystem Inflammatory Syndrome in Children.
    Biology (Basel). 2022 Mar 9;11(3):417. doi: 10.3390/biology11030417.
    https://pubmed.ncbi.nlm.nih.gov/35336791/

  • Gartini S, Bougrini Y, Rhazari M, Bourkadi JE.
    Macrophagic activation syndrome revealing disseminated multifocal tuberculosis: A case report of a rare clinical situation.
    Ann Med Surg (Lond). 2022 Mar 9;76:103487. doi: 10.1016/j.amsu.2022.103487.
    https://pubmed.ncbi.nlm.nih.gov/35299938/

 
FEBRERO 2022
  • Mathieu AL, Omarjee O, Walzer T, Belot A.
    Macrophage involvement in juvenile arthritis onset: LACC1 bridges the gap?.
    Med Sci (Paris). 2022 Feb;38(2):133-135. doi: 10.1051/medsci/2021253. Epub 2022 Feb 18.
    https://pubmed.ncbi.nlm.nih.gov/35179464/

 
ENERO 2022
  • AlNouwaiser DN, AlMutairi SS, AlRowailey AS.
    Management of Hepatitis A-induced Macrophage Activation Syndrome With Anakinra in Systemic Juvenile Idiopathic Arthritis: A Case Report.
    Cureus. 2022 Jan 19;14(1):e21430. doi: 10.7759/cureus.21430.
    https://pubmed.ncbi.nlm.nih.gov/35103223/

  • Bindoli S, Giollo A, Galozzi P, Doria A, Sfriso P.
    Hyperinflammation after anti-SARS-CoV-2 mRNA/DNA vaccines successfully treated with anakinra: Case series and literature review.
    Exp Biol Med (Maywood). 2022 Jan 22:15353702211070290. doi: 10.1177/15353702211070290.
    https://pubmed.ncbi.nlm.nih.gov/35068221/

 
DICIEMBRE 2021
  • Shimizu M.
    Macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Immunol Med. 2021 Dec;44(4):237-245. doi: 10.1080/25785826.2021.1912893. Epub 2021 May 13.
    https://pubmed.ncbi.nlm.nih.gov/33982649/

NOVIEMBRE 2021
  • Erkens R, Esteban Y, Towe C, Schulert G, Vastert S.
    Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis: Refractory Arthritis, Recurrent Macrophage Activation Syndrome and Chronic Lung Disease.
    Rheum Dis Clin North Am. 2021 Nov;47(4):585-606. doi: 10.1016/j.rdc.2021.06.003.
    https://pubmed.ncbi.nlm.nih.gov/34635293/

  • Iyengar VV, Chougule A, Gowri V, Taur P, Prabhu S, Bodhanwala M, Desai MM.
    DADA2 presenting as nonimmune hemolytic anemia with recurrent macrophage activation syndrome.
    Pediatr Blood Cancer. 2021 Nov 22:e29461. doi: 10.1002/pbc.29461. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34811889/

 
SEPTIEMBRE 2021
  • Yao H, Wang Y, Wang Z, Zhao J, Deng X, Zhang Z, et al.
    The performance of the diagnostic scoring system or criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis for adult-onset Still's disease. A multicentre case-control study in China.
    Clin Exp Rheumatol. 2021 Sep-Oct;39 Suppl 132(5):129-134. Epub 2021 Sep 30.
    https://pubmed.ncbi.nlm.nih.gov/34596030/

  • Gouda W, Alsaqabi F, Moshrif A, Abbas AS, Abdel-Aziz TM, Islam MA.
    Macrophage activation syndrome triggered by systemic lupus erythematosus flare: successful treatment with a combination of dexamethasone sodium phosphate, intravenous immunoglobulin, and cyclosporine: a case report.
    J Med Case Rep. 2021 Oct 7;15(1):497. doi: 10.1186/s13256-021-03072-1.
    https://pubmed.ncbi.nlm.nih.gov/34620236/

 
AGOSTO 2021
  • Zhang G, Liu W, Zhang X, Liu L.
    Rescued from desperation: adult-onset Still's disease with life-threatening interstitial lung disease and macrophage activation: Successful treatment by Tocilizumab.
    Z Rheumatol. 2021 Aug 10. doi: 10.1007/s00393-021-01063-7. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34378080/

  • Reiff DD, Cron RQ.
    Performance of Cytokine Storm Syndrome Scoring Systems in Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children.
    ACR Open Rheumatol. 2021 Aug 25. doi: 10.1002/acr2.11331. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34431626/

JULIO 2021
  • Gao DK, Salomonis N, Henderlight M, Woods C, Thakkar K, Grom AA, Thornton S, Jordan MB, Wikenheiser-Brokamp KA, Schulert GS.
    IFN-gamma is essential for alveolar macrophage driven pulmonary inflammation in macrophage activation syndrome CI Insight. 2021 Jul 27:147593. doi:
    10.1172/jci.insight.147593. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34314387/

  • Ashkenazi L, Hashkes PJ.
    50 Years Ago in The Journal of Pediatrics: Hepatic Dysfunction in Systemic Juvenile Idiopathic Arthritis with Alleviation of Arthritis: The First Description of Macrophage Activation Syndrome?
    J Pediatr. 2021 Jul;234:64. doi: 10.1016/j.jpeds.2021.03.042.
    https://pubmed.ncbi.nlm.nih.gov/34172168/

  

JUNIO 2021
  • Omkar Phadke, Kelly Rouster-Stevens, Helen Giannopoulos, Shanmuganathan Chandrakasan, Sampath Prahalad.
    Intravenous administration of anakinra in children with macrophage activation syndrome.
    Pediatr Rheumatol Online J. 2021 Jun 29;19(1):98. doi: 10.1186/s12969-021-00585-3.
    https://pubmed.ncbi.nlm.nih.gov/34187503/

 

MAYO 2021
  • Akturk H, Tanyildiz M, Erbey F, Tasdemir M, Celikyurt A, Gonen E, Bilge I.
    Macrophage Activation Syndrome in a Child with Juvenile Idiopathic Arthritis Secondary to SARS-CoV-2.
    J Trop Pediatr. 2021 May 24:fmab049. doi: 10.1093/tropej/fmab049. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/34028559/

 

MARZO 2021
  • McGonagle D, Ramanan AV, Bridgewood C.
    Immune cartography of macrophage activation syndrome in the COVID-19 era
    Nat Rev Rheumatol. 2021 Mar;17(3):145-157. doi: 10.1038/s41584-020-00571-1.
    https://pubmed.ncbi.nlm.nih.gov/33547426/

  • Naveen R, Jain A, Muhammed H, Gupta L, Misra DP, Lawrence A, Agarwal V, Misra R, Aggarwal A.
    Macrophage activation syndrome in systemic lupus erythematosus and systemic-onset juvenile idiopathic arthritis: a retrospective study of similarities and dissimilarities.
    Rheumatol Int. 2021 Mar;41(3):625-631. doi: 10.1007/s00296-020-04763-6.
    https://pubmed.ncbi.nlm.nih.gov/33388903/

  • Yamabe T, Ohmura SI, Uehara K, Naniwa T.
    Macrophage activation syndrome in patients with adult-onset Still's disease under tocilizumab treatment. A single-center observational study.
    Mod Rheumatol. 2021 Mar 10:1-21. doi: 10.1080/14397595.2021.1899565. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/33719871/

  • Paim LB, Landim MLL, Firmino SL, Monteiro CMBE, Cordeiro LR, de Araujo FG, de Carvalho JF.
    Canakinumab for Pulmonary Artery Hypertension and Macrophage Activation Syndrome Associated with Uncontrolled Systemic Juvenile Idiopathic Arthritis.
    Indian J Pediatr. 2021 Mar 20. doi: 10.1007/s12098-021-03734-4. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/33742412/

 

FEBRERO 2021 

  • Horne A, von Bahr Greenwood T, Chiang SCC, Meeths M, Björklund C, Ekelund M, Erensjö P, Berg S, Hagelberg S, Bryceson YT, Andersson U, Henter JI.
    Efficacy of moderately dosed etoposide in macrophage activation syndrome - hemophagocytic lymphohistiocytosis (MAS-HLH).
    J Rheumatol. 2021 Feb 15:jrheum.200941. doi: 10.3899/jrheum.200941.
    https://pubmed.ncbi.nlm.nih.gov/33589555/ 
  • Guo L, Xu Y, Qian X, Zou L, Zheng R, Teng L, Zheng Q, Leung Jung LK, Lu M.J 
    Sudden Hypotension and Increased Serum IFN-gamma and IL-10 Predict Early Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis Patients.
    Pediatr. 2021 Feb 10:S0022-3476(21)00117-7. doi: 10.1016/j.jpeds.2021.02.008. 
    https://pubmed.ncbi.nlm.nih.gov/33581106/ 

  •  Aydın F, Çelikel E, Ekici Tekin Z, Coşkun S, Sezer M, Karagöl C, Kaplan MM, Tekgöz N, Kurt T, Özcan S, Kavurt AV, Özkaya Parlakay A, Çelikel Acar B.
    Comparison of baseline laboratory findings of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis and multisystem inflammatory syndrome in children.
    Int J Rheum Dis. 2021 Feb 7. doi: 10.1111/1756-185X.14078. 
    https://pubmed.ncbi.nlm.nih.gov/33550678/ 

  • Naveen R, Jain A, Muhammed H, Gupta L, Misra DP, Lawrence A, Agarwal V, Misra R, Aggarwal A.
    Macrophage activation syndrome in systemic lupus erythematosus and systemic-onset juvenile idiopathic arthritis: a retrospective study of similarities and dissimilarities.
    Rheumatol Int. 2021 Mar;41(3):625-631. doi: 10.1007/s00296-020-04763-6. Epub 2021 Jan 2.
    https://pubmed.ncbi.nlm.nih.gov/33388903/

  •  McGonagle D, Ramanan AV, Bridgewood C.
    Immune cartography of macrophage activation syndrome in the COVID-19 era
    Nat Rev Rheumatol. 2021 Mar;17(3):145-157. doi: 10.1038/s41584-020-00571-1.
    https://pubmed.ncbi.nlm.nih.gov/33547426/

 

NOVIEMBRE 2020
  • Sag E, Keskin A, Atalay E, Demir S, Cuceoglu MK, Akca UK, Batu ED, Bilginer Y, Ozen S.
    Performances of the "MS-score" and "HScore" in the diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis patients.
    Rheumatol Int. 2020 Nov 19. doi: 10.1007/s00296-020-04750-x.
    https://pubmed.ncbi.nlm.nih.gov/33215249/

 

OCTUBRE 2020
  • Krei JM, Møller HJ, Larsen JB.
    The role of interleukin-18 in the diagnosis and monitoring of hemophagocytic lymphohistiocytosis/macrophage activation syndrome - a systematic review.
    Clin Exp Immunol. 2020 Oct 31. doi: 10.1111/cei.13543. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/33128796/

 

SEPTIEMBRE 2020
  • Ke Y, Lv C, Xuan W, Wu J, Da Z, Wei H, Zhang M, Tan W.
    Clinical analysis of macrophage activation syndrome in adult rheumatic disease: A multicenter retrospective study.
    Int J Rheum Dis. 2020 Sep 3. doi: 10.1111/1756-185X.13955. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/32885598/
  • Ruscitti P, Bruno F, Berardicurti O, Acanfora C, Pavlych V, Palumbo P, Conforti A, Carubbi F, Di Cola I, Di Benedetto P, Cipriani P, Grassi D, Masciocchi C, Iagnocco A, Barile A, Giacomelli R.
    Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences.
    Ann Rheum Dis. 2020 Sep;79(9):1152-1155. doi: 10.1136/annrheumdis-2020-218048.
    https://pubmed.ncbi.nlm.nih.gov/32719039/

 

AGOSTO 2020
  • Otsuka R, Seino KI
    Macrophage activation syndrome and COVID-19.
    Inflamm Regen. 2020 Aug 6;40:19. doi: 10.1186/s41232-020-00131-w.
    https://pubmed.ncbi.nlm.nih.gov/32834892/
  • Kübler L, Bittmann I, Kuipers JG.
    Macrophage activation syndrome triggered by active systemic lupus erythematosus: Successful treatment by interleukin-1 inhibition (anakinra)
    Z Rheumatol. 2020 Aug 17. doi: 10.1007/s00393-020-00836-w.
    https://pubmed.ncbi.nlm.nih.gov/32804304/
  • Loomba RS, Villarreal EG, Flores S.
    COVID-19 and Hyperinflammatory Syndrome in Children: Kawasaki Disease with Macrophage Activation Syndrome in Disguise?
    Cureus. 2020 Aug 1;12(8):e9515. doi: 10.7759/cureus.9515.
    https://pubmed.ncbi.nlm.nih.gov/32884871/

 

JULIO 2020
  • Mizuta M, Shimizu M, Irabu H, Usami M, Inoue N, Nakagishi Y, Wada T, Yachie A.
    Comparison of serum cytokine profiles in macrophage activation syndrome complicating different background rheumatic diseases in children.
    Rheumatology (Oxford). 2020 Jul 18:keaa299. doi: 10.1093/rheumatology/keaa299. Epub ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/32681176/

 

MAYO 2020
  • Pal P, Bose N, Poddar A, Chowdhury K, Saha A.
    Experience with Cidofovir as an adjunctive therapy in a patient of adenovirus-induced macrophage activation syndrome in systemic arthritis.
    Clin Rheumatol. 2020 May 17:1–4.
    https://doi.org/10.1007/s10067-020-05133-0

 

MARZO 2020
  • Cron RQ, Chatham WW.
    The Rheumatologist's Role in Covid-19.
    J Rheumatol. 2020 Mar 24. pii: jrheum.200334. doi: 10.3899/jrheum.200334. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/32209661
  • Irabu H, Shimizu M, Kaneko S, Inoue N, Mizuta M, Nakagishi Y, Yachie A.
    Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis during tocilizumab therapy.
    Pediatr Res. 2020 Mar 17. doi: 10.1038/s41390-020-0843-4. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/32184444

 

FEBRERO 2020
  • Alongi A, Naddei R, De Miglio L, Natoli V, Ravelli A.
    Macrophage activation syndrome in pediatrics.Pediatr Allergy Immunol. 2020 Feb;31 Suppl 24:13-15. doi: 10.1111/pai.13158.
    https://www.ncbi.nlm.nih.gov/pubmed/32017214

 

ENERO 2020
  • Shimizu M, Mizuta M, Okamoto N, Yasumi T, Iwata N, Umebayashi H, Okura Y, Kinjo N, Kubota T, Nakagishi Y, Nishimura K, Mohri M, Yashiro M, Yasumura J, Wakiguchi H, Mori M.
    Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Pediatr Rheumatol Online J. 2020 Jan 10;18(1):2. doi: 10.1186/s12969-020-0399-1.
    https://www.ncbi.nlm.nih.gov/pubmed/31924225

 

NOVIEMBRE 2019
  • Henderson LA, Cron RQ.
    Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management.
    Paediatr Drugs. 2020 Feb;22(1):29-44. doi: 10.1007/s40272-019-00367-1.
    https://www.ncbi.nlm.nih.gov/pubmed/31732958

 

OCTUBRE 2019
  • Zou LX, Zhu Y, Sun L, Ma HH, Yang SR, Zeng HS, Xiao JH, Yu HG, Guo L, Xu YP, Lu MP.
    Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China
    World J Pediatr. 2019 Oct 14. doi: 10.1007/s12519-019-00256-0. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/31612427

 

SEPTIEMBRE 2019

  • Eloseily EM, Weiser P, Crayne CB, Haines H, Mannion ML, Stoll ML, Beukelman T, Atkinson TP, Cron RQ.
    Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis.
    Arthritis Rheumatol. 2019 Sep 12. doi: 10.1002/art.41103. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/31513353
  • Prencipe G, Bracaglia C, De Benedetti F.
    Interleukin-18 in pediatric rheumatic diseases.
    Curr Opin Rheumatol. 2019 Sep;31(5):421-427. doi:10.1097/BOR.0000000000000634.
    https://www.ncbi.nlm.nih.gov/pubmed/31192813

 

AGOSTO 2019
  • Lind-Holst M, Hartling UB, Christensen AE.
    High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant.
    BMJ Case Rep. 2019 Aug 4;12(8).
    https://www.ncbi.nlm.nih.gov/pubmed/31383678
  • Lin Q, Zhang M, Tang H, Shen Y, Zhu Y, Xu Q, Li X.
    Acute pancreatitis and macrophage activation syndrome in pediatric systemic lupus erythematosus: case-based review.
    Rheumatol Int. 2019 Aug 3. doi: 10.1007/s00296-019-04388-4.
    https://www.ncbi.nlm.nih.gov/pubmed/31377830
  • Takakura M, Shimizu M, Irabu H, Sakumura N, Inoue N, Mizuta M, Nakagishi Y, Yachie A.
    Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Clin Immunol. 2019 Aug 23:108252.
    https://www.ncbi.nlm.nih.gov/pubmed/31449879

 

JULIO 2019
  • Minoia F, Bovis F, Davì S, Horne A, Fischbach M, Frosch M, Huber A, Jelusic M, Sawhney S, McCurdy DK, Silva CA, Rigante D, Unsal E, Ruperto N, Martini A, Cron RQ, Ravelli A; PRINTO, CARRA, the PRCSG and the Histiocyte Society.
    Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Ann Rheum Dis. 2019 Jul 11. pii: annrheumdis-2019-215211. doi: 10.1136/annrheumdis-2019-215211. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/31296501
  • Yasin S, Fall N, Brown RA, Henderlight M, Canna SW, Girard-Guyonvarc'h C, Gabay C, Grom AA, Schulert GS.
    IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome.
    Rheumatology (Oxford). 2019 Jul 20. pii: kez282. doi: 10.1093/rheumatology/kez282. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/31326996
  • Mizuta M, Shimizu M, Inoue N, Nakagishi Y, Yachie A.
    Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome.
    Cytokine. 2019 Jul;119:182-187.
    https://www.ncbi.nlm.nih.gov/pubmed/30952065

 

FEBRERO 2019
  • Crayne CB, Albeituni S, Nichols KE, Cron RQ.
    The Immunology of Macrophage Activation Syndrome.
    Front Immunol. 2019 Feb 1;10:119. doi: 10.3389/fimmu.2019.00119. eCollection 2019.
    https://www.ncbi.nlm.nih.gov/pubmed/30774631

 

SEPTIEMBRE 2018
  • Yasin S, Schulert GS.
    Systemic juvenile idiopathic arthritis and macrophage activation syndrome: update on pathogenesis and treatment.
    Curr Opin Rheumatol. 2018 Sep;30(5):514-520
    https://www.ncbi.nlm.nih.gov/pubmed/29870499

 

AGOSTO 2018
  • Lerkvaleekul B, Vilaiyuk S.
    Macrophage activation syndrome: early diagnosis is key.
    Open Access Rheumatol. 2018 Aug 31;10:117-128. doi: 10.2147/OARRR.S151013. eCollection 2018.
    https://www.ncbi.nlm.nih.gov/pubmed/30214327

 

ABRIL 2018
  • Sönmez HE, Demir S, Bilginer Y, Özen S.
    Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature.
    Clin Rheumatol. 2018 Apr 16. doi: 10.1007/s10067-018-4095-1. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/29663156
  • Arthur VL, Shuldiner E, Remmers EF, Hinks A, Grom AA, Foell D, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Ilowite NT, Mellins ED, Russo R, Len C, Oliveira S, Yeung RSM, Rosenberg AM, Wedderburn LR, Anton J, Haas JP, Rösen-Wolff A, Minden K, Szymanski AM, Thomson W, Kastner DL, Woo P, Ombrello MJ
    IL1RN Variation Influences both Disease Susceptibility and Response to Human Recombinant IL-1RA Therapy in Systemic Juvenile Idiopathic Arthritis.
    Arthritis Rheumatol. 2018 Apr 2. doi: 10.1002/art.40498. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29609200

 

FEBRERO 2018

 

ENERO 2018
  • Borgia RE, Gerstein M, Levy DM, Silverman ED, Hiraki LT.
    Features, Treatment and Outcomes of Macrophage Activation Syndrome in Childhood-onset Systemic Lupus Erythematosus.
    Arthritis Rheumatol. 2018 Jan 17. doi: 10.1002/art.40417. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/29342508
  • Schulert GS, Minoia F, Bohnsack J, Cron RQ, Hashad S, KonÉ-Paut I, Kostik M, Lovell D, Maritsi D, Nigrovic PA, Pal P, Ravelli A, Shimizu M, Stanevicha V, Vastert S, Woerner A, de Benedetti F, Grom AA.
    Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation SyndromeAssociated With Systemic Juvenile Idiopathic Arthritis.
    Arthritis Care Res (Hoboken). 2017 May 12. doi: 10.1002/acr.23277. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/28499329

 

DICIEMBRE 2017
  • Ruscitti P, Rago C, Breda L, Cipriani P, Liakouli V, Berardicurti O, Carubbi F, Di Battista C, Verrotti A, Giacomelli R.
    Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients.
    Clin Rheumatol. 2017 Dec;36(12):2839-2845.
    https://www.ncbi.nlm.nih.gov/pubmed/28914368
  • Shimizu M, Mizuta M, Yasumi T, Iwata N, Okura Y, Kinjo N, Umebayashi H, Kubota T, Nakagishi Y, Nishimura K, Yashiro M, Yasumura J, Yamazaki K, Wakiguchi H, Okamoto N, Mori M.
    Validation of classification criteria of macrophage activation syndrome in Japanese patients with systemic juvenile idiopathic arthritis.
    Arthritis Care Res (Hoboken). 2017 Dec 1. doi: 10.1002/acr.23482. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29195002https://www.ncbi.nlm.nih.gov/pubmed/29195002
  • Núñez Cuadros E, Cabrera Del Moral A, Jiménez Hinojosa JM, Leiva Gea I, Conejo Muñoz L.
    [Haemophagocytic syndrome secondary to endocarditis due to Bartonella henselae].
    An Pediatr (Barc). 2017 Dec 7. pii: S1695-4033(17)30450-2. doi: 10.1016/j.anpedi.2017.11.004. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29233492

 

NOVIEMBRE 2017
  • Ruscitti P, Cipriani P, Di Benedetto P, Liakouli V, Carubbi F, Berardicurti O, Ciccia F, Guggino G, Triolo G, Giacomelli R.
    Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?
    Expert Rev Clin Immunol. 2017 Nov;13(11):1041-1047
    https://www.ncbi.nlm.nih.gov/pubmed/28837367

 

OCTUBRE 2017
  • Grom AA.
    Primary Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome: The Importance of Timely Clinical Differentiation.
    J Pediatr. 2017 Oct;189:19-21.e1. doi: 10.1016/j.jpeds.2017.07.025.
    https://www.ncbi.nlm.nih.gov/pubmed/28838727
  • Minoia F, Bovis F, Davì S, Insalaco A, Lehmberg K, Shenoi S, et al.
    Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome.
    J Pediatr. 2017 Oct;189:72-78.e3. doi: 10.1016/j.jpeds.2017.06.005.
    https://www.ncbi.nlm.nih.gov/pubmed/28807357

 

AGOSTO 2017
  • Grom AA.
    Primary Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome: The Importance of Timely Clinical Differentiation.
    J Pediatr. 2017 Aug 21. pii: S0022-3476(17)30959-9. doi: 10.1016/j.jpeds.2017.07.025. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28838727
  • Shimizu M, Inoue N, Mizuta M, Nakagishi Y, Yachie A.
    Characteristic elevation of soluble TNF receptor II : I ratio in macrophage activation syndrome with systemic juvenile idiopathic arthritis.
    Clin Exp Immunol. 2017 Aug 16. doi: 10.1111/cei.13026. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28815559
  • Minoia F, Bovis F, Davì S, Insalaco A, Lehmberg K, Shenoi S, Weitzman S, Espada G, Gao YJ, Anton J, Kitoh T, Kasapcopur O, Sanner H, Merino R, Astigarraga I15, Alessio M, Jeng M, Chasnyk V, Nichols KE, Huasong Z, Li C, Micalizzi C, Ruperto N, Martini A, Cron RQ, Ravelli A, Horne A; Pediatric Rheumatology International Trials Organization, the Childhood Arthritis and Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group, and the Histiocyte Society.
    Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome.
    J Pediatr. 2017 Aug 11. pii: S0022-3476(17)30783-7. doi: 10.1016/j.jpeds.2017.06.005. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28807357
  • Huang R, Hayashi Y, Yan X, Bu J, Wang J, Zhang Y, Zhou Y, Tang Y, Wu L, Xu Z, Liu X, Wang Q, Zhou J, Xiao Z, Bridges JP, Marsh RA, Zhang, Jordan MB, Li Y, Huang G
    HIF1A is a critical downstream mediator for hemophagocytic lymphohistiocytosis.
    Haematologica. 2017 Aug 31. pii: haematol.2017.174979. doi: 10.3324/haematol.2017.174979. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28860338

 

JUNIO 2017

 

MAYO 2017

 

ABRIL 2017
  • Ahn SS, Yoo BW, Jung SM, Lee SW, Park YB, Song JJ.
    Application of the 2016 EULAR/ACR/PRINTO Classification Criteria for Macrophage Activation Syndrome in Patients with Adult-onset Still Disease
    J Rheumatol. 2017 Apr 15. pii: jrheum.161286. doi: 10.3899/jrheum.161286. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28412707
  • Liu AC, Yang Y, Li MT, Jia Y, Chen S, Ye S, Zeng XZ, Wang Z, Zhao JX, Liu XY, Zhu J, Zhao Y, Zeng XF, Li ZG.
    Macrophage activation syndrome in systemic lupus erythematosus: a multicenter, case-control study in China
    Clin Rheumatol. 2017 Apr 13. doi: 10.1007/s10067-017-3625-6. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28409239 

 

MAYO 2017

 

ABRIL 2017
  • Ahn SS, Yoo BW, Jung SM, Lee SW, Park YB, Song JJ.
    Application of the 2016 EULAR/ACR/PRINTO Classification Criteria for Macrophage Activation Syndrome in Patients with Adult-onset Still Disease
    J Rheumatol. 2017 Apr 15. pii: jrheum.161286. doi: 10.3899/jrheum.161286. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28412707
  • Liu AC, Yang Y, Li MT, Jia Y, Chen S, Ye S, Zeng XZ, Wang Z, Zhao JX, Liu XY, Zhu J, Zhao Y, Zeng XF, Li ZG.
    Macrophage activation syndrome in systemic lupus erythematosus: a multicenter, case-control study in China
    Clin Rheumatol. 2017 Apr 13. doi: 10.1007/s10067-017-3625-6. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28409239

 

MARZO 2017
  • Shi L, Hu F, Xu C, Zhu H, Qie D, Yuan C, Tao Y, Liu H.
    Plasma exchange successfully treated macrophage activation syndrome in rheumatoid factor-positive polyarticular juvenile idiopathic arthritis with combined pneumonia.
    Int J Rheum Dis. 2017 Mar 22. doi: 10.1111/1756-185X.13064.
    https://www.ncbi.nlm.nih.gov/pubmed/28328098
  • Ahn SS, Yoo BW, Jung SM, Lee SW, Park YB, Song JJ.
    In-hospital mortality in febrile lupus patients based on 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome.
    Semin Arthritis Rheum. 2017 Feb 8. pii: S0049-0172(16)30373-0. doi: 10.1016/j.semarthrit.2017.02.002. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/28268026

 

FEBRERO 2017

 

ENERO 2017
  • Bracaglia C, Prencipe G, De Benedetti F.
    Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome.
    Pediatr Rheumatol Online J. 2017 Jan 17;15(1):5. doi: 10.1186/s12969-016-0130-4.
    https://www.ncbi.nlm.nih.gov/pubmed/28095869

 

DICIEMBRE 2016
  • Palman J, May J, Pilkington C.
    Macrophage activation syndrome triggered by coeliac disease: a unique case report.
    Pediatr Rheumatol Online J. 2016 Dec 9;14(1):66.
    https://www.ncbi.nlm.nih.gov/pubmed/27938384
  • Bracaglia C, de Graaf K, Pires Marafon D, Guilhot F, Ferlin W, Prencipe G, Caiello I, Davì S, Schulert G, Ravelli A, Grom AA, de Min C, De Benedetti F.
    Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Ann Rheum Dis. 2017 Jan;76(1):166-172.
    https://www.ncbi.nlm.nih.gov/pubmed/27296321

 

NOVIEMBRE 2016
  • García-Montoya L, Sáenz-Tenorio CN, Janta I, Menárguez J, López-Longo FJ, Monteagudo I, Naredo E.
    Hemophagocytic lymphohistiocytosis in a patient with Sjögren's syndrome: case report and review.
    Rheumatol Int. 2016 Nov 16.
    https://www.ncbi.nlm.nih.gov/pubmed/27853859

 

OCTUBRE 2016
  • Aytaç S, Batu ED, Ünal Ş, Bilginer Y, Çetin M, Tuncer M, Gümrük F, Özen S.
    Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus
    Rheumatol Int. 2016 Oct;36(10):1421-9
    https://www.ncbi.nlm.nih.gov/pubmed/27510530

 

SEPTIEMBRE 2016
  • Hernández-Jiménez P,Díaz-Pedroche C, Laureiro J, Madrid O, Martín E, Lumbreras C.
    Hemophagocytic lymphohistiocytosis: Analysis of 18 cases.
    Med Clin (Barc). 2016 Oct 7.
    https://www.ncbi.nlm.nih.gov/pubmed/27726848
  • Wunderlich M, Stockman C, Devarajan M, Ravishankar N, Sexton C, Kumar AR, Mizukawa B, Mulloy JC.
    A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment.
    JCI Insight. 2016 Sep 22;1(15):e88181.
    https://www.ncbi.nlm.nih.gov/pubmed/27699249
  • Thomas W, Veer MV, Besser M.
    Haemophagocytic lymphohistiocytosis: an elusive syndrome.
    Clin Med (Lond). 2016 Oct;16(5):432-436.
    https://www.ncbi.nlm.nih.gov/pubmed/27697804
  • Ruscitti P, Cipriani P, Ciccia F, Masedu F, Liakouli V, Carubbi F, Berardicurti O, Guggino G, Di Benedetto P, Di Bartolomeo S, Valenti M, Triolo G,  Giacomelli R.
    Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers.
    Autoimmun Rev. 2016 Sep 21. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/27664384
  • Crayne CB, Khatami KS, Galliano G.
    Macrophage Activation Syndrome.
    Clin Pediatr (Phila). 2016 Oct;55(11):1001-4.
    https://www.ncbi.nlm.nih.gov/pubmed/27562237

 

AGOSTO 2016
  • Aytaç S, Batu ED, Ünal Ş, Bilginer Y, Çetin M, Tuncer M, Gümrük F, Özen S.
    Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.
    Rheumatol Int. 2016 Oct;36(10):1421-9.
    http://www.ncbi.nlm.nih.gov/pubmed/27510530
  • Bracaglia C, de Graaf K, Pires Marafon D, Guilhot F, Ferlin W, Prencipe G, Caiello I, Davì S, Schulert G, Ravelli A, Grom AA, de Min C, De Benedetti F.
    Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Ann Rheum Dis. 2016 Jun 13. pii: annrheumdis-2015-209020. doi: 10.1136/annrheumdis-2015-209020. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/27296321

 

JUNIO 2016
  • Gormezano NW, Otsuzi CI, Barros DL, da Silva MA, Pereira RM, Campos LM, Borba EF, Bonfá E, Silva CA.
    Macrophage activation syndrome: A severe and frequent manifestation of acute pancreatitis in 362 childhood-onset compared to 1830 adult-onset systemic lupus erythematosus patients.
    Semin Arthritis Rheum. 2016 Jun;45(6):706-10. doi: 10.1016/j.semarthrit.2015.10.015
    http://www.ncbi.nlm.nih.gov/pubmed/26833399

 

MARZO 2016
  • Grom AA, Horne A, De Benedetti F.
    Macrophage activation syndrome in the era of biologic therapy.
    Nat Rev Rheumatol. 2016 Mar 24. doi: 10.1038/nrrheum.2015.179. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/27009539

 

FEBRERO 2016
  • Put K, Brisse E, Avau A, Imbrechts M, Mitera T, Janssens R, Proost P, Fallarino F, Wouters CH, Matthys P.
    IDO1 Deficiency Does Not Affect Disease in Mouse Models of Systemic Juvenile Idiopathic Arthritis and Secondary Hemophagocytic Lymphohistiocytosis.
    PLoS One. 2016 Feb 25;11(2):e0150075. doi: 10.1371/journal.pone.0150075. eCollection 2016.
    http://www.ncbi.nlm.nih.gov/pubmed/26914138
  • Tasaki Y, Shimizu M, Inoue N, Mizuta M, Nakagishi Y, Wada T, Yachie A.
    Disruption of vascular endothelial homeostasis in systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The dynamic roles of angiopoietin-1 and -2.
    Cytokine. 2016 Feb 20;80:1-6. doi: 10.1016/j.cyto.2016.02.008. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26908294

 

ENERO 2016
  • Grom AA, Ilowite NT, Pascual V, Brunner HI, Martini A, Lovell D, Ruperto N; Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group, Leon K, Lheritier K, Abrams K.
    Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.
    Arthritis Rheumatol. 2016 Jan;68(1):218-28. doi: 10.1002/art.39407.
    http://onlinelibrary.wiley.com/doi/10.1002/art.39407/abstract

 

DICIEMBRE 2015
  • Boom V, Anton J, Lahdenne P, Quartier P, Ravelli A, Wulffraat NM, Vastert SJ
    Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Pediatr Rheumatol Online J. 2015 Dec 3;13(1):55. doi: 10.1186/s12969-015-0055-3.
    http://www.ncbi.nlm.nih.gov/pubmed/26634252

 

OCTUBRE 2015
  • Ravelli A, Davì S, Minoia F, Martini A, Cron RQ.
    Macrophage Activation Syndrome
    Hematol Oncol Clin North Am. 2015 Oct;29(5):927-41.
    http://www.ncbi.nlm.nih.gov/pubmed/26461152
  • Ravelli A, Minoia F, Davì S, Horne A, Bovis F, Pistorio A, Aricò M, Avcin T, Behrens EM, De Benedetti F, Filipovich L, Grom AA, Henter JI, Ilowite NT, Jordan MB, Khubchandani R, Kitoh T, Lehmberg K, Lovell DJ, Miettunen P, Nichols KE, Ozen S, Pachlopnick-Schmid J, Ramanan AV, Russo R, Schneider R, Sterba G, Uziel Y, Wallace C, Wouters C, Wulffraat N, Demirkaya E, Brunner HI, Martini A, Ruperto N, Cron RQ; Pediatric Rheumatology International Trials Organization; Childhood Arthritis & Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society.
    Development and initial validation of classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Arthritis Rheumatol. 2015 Aug 28. doi: 10.1002/art.39332. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/26314788
  • Grom AA, Ilowite NT, Pascual V, Brunner HI, Martini A, Lovell D, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG), Leon K, Lheritier K, Abrams K.
    Canakinumab in Systemic Juvenile Idiopathic Arthritis: Impact on the Rate and Clinical Presentation of Macrophage Activation Syndrome.
    Arthritis Rheumatol. 2015 Aug 28. doi: 10.1002/art.39407. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26314396 

 

AGOSTO 2015
  • Cifaldi L, Prencipe G, Caiello I, Bracaglia C, Locatelli F, De Benedetti F, Strippoli R.
    Inhibition of Natural Killer Cell Cytotoxicity by Interleukin-6: Implications for the Pathogenesis of Macrophage Activation Syndrome.
    Arthritis Rheumatol. 2015 Aug 5. doi: 10.1002/art.39295. EPUB ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/26251193

 

JULIO 2015
  • Shimizu M, Nakagishi Y, Inoue N, Mizuta M, Ko G, Saikawa Y, Kubota T, Yamasaki Y, Takei S, Yachie A
    Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Clin Immunol. 2015 Jun 20;160(2):277-281. doi: 10.1016/j.clim.2015.06.005. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26101092

 

JUNIO 2015
  • Minoia F, Davì S, Horne A, Bovis F, Demirkaya E, Akikusa J, Ayaz NA, Al-Mayouf SM, Barone P, Bica B, Bolt I, Breda L, De Cunto C, Enciso S, Gallizzi R, Griffin T, Hennon T, Horneff G, Jeng M, Kapovic AM, Lipton JM, Magni Manzoni S, Rumba-Rozenfelde I, Magalhaes CS, Sewairi WM, Stine KC, Vougiouka O, Weaver LK, Davidsone Z, De Inocencio J, Ioseliani M, Lattanzi B, Tezer H, Buoncompagni A, Picco P, Ruperto N, Martini A, Cron RQ, Ravelli A; Pediatric Rheumatology International Trials Organization; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; and the Histiocyte Society.
    Dissecting the Heterogeneity of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis.
    J Rheumatol June 2015 42(6):994-1001, doi:10.3899/jrheum.141261
    http://www.ncbi.nlm.nih.gov/pubmed/25877504

 

ABRIL 2015
  • Minoia F, Davì S, Horne A, Bovis F, Demirkaya E, Akikusa J, Ayaz NA, Al-Mayouf SM, Barone P, Bica B, Bolt I, Breda L, De Cunto C, Enciso S, Gallizzi R, Griffin T, Hennon T, Horneff G, Jeng M, Kapovic AM, Lipton JM, Magni Manzoni S, Rumba-Rozenfelde I, Magalhaes CS, Sewairi WM, Stine KC, Vougiouka O, Weaver LK, Davidsone Z, De Inocencio J, Ioseliani M, Lattanzi B, Tezer H, Buoncompagni A, Picco P, Ruperto N, Martini A, Cron RQ, Ravelli A; Pediatric Rheumatology International Trials Organization; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; and the Histiocyte Society.
    issecting the Heterogeneity of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis.
    J Rheumatol. 2015 Apr 15. pii: jrheum.141261. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/25877504  
  • Rigante D, Emmi G, Fastiggi M, Silvestri E, Cantarini L.
    Macrophage activation syndrome in the course of monogenic autoinflammatory disorders.

    Clin Rheumatol. 2015 Apr 8. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/25846831

 

MARZO 2015
  • Put K, Avau A, Brisse E, Mitera T, Put S, Proost P, Bader-Meunier B, Westhovens R, Van den Eynde BJ, Orabona C, Fallarino F, De Somer L, Tousseyn T, Quartier P, Wouters C, Matthys P.
    Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ.
    Rheumatology (Oxford). 2015 Mar 12. pii: keu524. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/25767156

 

FEBRERO 2015
  • Yokota S, Itoh Y, Morio T, Sumitomo N, Daimaru K, Minota S.
    Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab.
    J Rheumatol. 2015 Feb 15.
    http://www.ncbi.nlm.nih.gov/pubmed/25684767

 

SEPTIEMBRE 2014
  • Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, Coppo P, Hejblum G.
    Development and validation of a score for the diagnosis of reactive hemophagocytic syndrome (HScore).
    Arthritis Rheumatol. 2014 Sep; 66(9):2613-2620.
    http://www.ncbi.nlm.nih.gov/pubmed/24782338

 

JULIO 2014
  • Davì S, Minoia F, Pistorio A, Horne A, Consolaro A, Rosina S, Bovis F et al on behalf of the Pediatric Rheumatology International Trials Organization; the Childhood Arthritis & Rheumatology Research Alliance; the Pediatric Rheumatology Collaborative Study Group; the Histiocyte Society.
    Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Arthritis Rheumatol. 2014 Jul 7. doi: 10.1002/art.38769. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/25044674
  • Kaufman KM, Linghu B, Szustakowski JD, Husami A, Yang F, Zhang K, Filipovich A, Fall N, Harley JB, Nirmala NR, Grom AA.
    Whole exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis.
    Arthritis Rheumatol. 2014 Jul 21. doi: 10.1002/art.38793. [Epub ahead of print].
    http://www.ncbi.nlm.nih.gov/pubmed/25047945
  • Minoia F, Davì S, Horne A, Demirkaya E, Bovis F, Li C et al on behalf of the Pediatric Rheumatology International Trials Organization; the Childhood Arthritis& Rheumatology Research Alliance; the Pediatric Rheumatology Collaborative Study Group, and the Histiocyte Society.
    Clinical features, treatment and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. A multinational, multicenter study of 362 patients.
    Arthritis Rheumatol. 2014 Jul 30. doi: 10.1002/art.38802.
    http://www.ncbi.nlm.nih.gov/pubmed/25077692

 

MAYO 2014
  • Poddighe D, Cavagna L, Brazzelli V, Bruni P, Marseglia GL.
    A hyper-ferritinemia syndrome evolving in recurrent macrophage activation syndrome, as an onset of amyopathic juvenile dermatomyositis: A challenging clinical case in light of the current diagnostic criteria.
    Autoimmun Rev. 2014 May 29. pii: S1568-9972(14)00128-1. doi: 10.1016/j.autrev.2014.05.009. [Epub ahead of print].
    http://www.ncbi.nlm.nih.gov/pubmed/24879966

 

ENERO 2014
  • Reddy VV, Myles A, Cheekatla SS, Singh S, Aggarwal A.
    Soluble CD25 in serum: a potential marker for subclinical macrophage activation syndrome in patients with active systemic onset juvenile idiopathic arthritis.
    Int J Rheum Dis. 2014 Jan 13. doi: 10.1111/1756-185X.12196. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24417800

 

JUNIO 2013
  • Lehmberg K, Pink I, Eulenburg C, Beutel K, Maul-Pavicic A, Janka G.
    Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis.
    J Pediatr. 2013 Jun;162(6):1245-51. doi: 10.1016/j.jpeds.2012.11.081. Epub 2013 Jan 17.
    http://www.ncbi.nlm.nih.gov/pubmed/23333131

 

MAYO 2013
  • Kahn PJ,Cron RQ
    Higher-dose Anakinra Is Effective in a Case of Medically Refractory Macrophage Activation Syndrome.
    J Rheumatol 2013 May;40(5):743-4. doi: 10.3899/jrheum.121098.
    http://www.ncbi.nlm.nih.gov/pubmed/23637382

 
PATROCINADORES